ANSOLYSEN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ansolysen, and when can generic versions of Ansolysen launch?
Ansolysen is a drug marketed by Wyeth Ayerst and is included in one NDA.
The generic ingredient in ANSOLYSEN is pentolinium tartrate. Additional details are available on the pentolinium tartrate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ANSOLYSEN?
- What are the global sales for ANSOLYSEN?
- What is Average Wholesale Price for ANSOLYSEN?
Summary for ANSOLYSEN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 22 |
| DailyMed Link: | ANSOLYSEN at DailyMed |
US Patents and Regulatory Information for ANSOLYSEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wyeth Ayerst | ANSOLYSEN | pentolinium tartrate | INJECTABLE;INJECTION | 009372-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
